{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:17:59Z","timestamp":1793139479925,"version":"4.5.0"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2021,3,2]]},"DOI":"10.1001\/jama.2021.0669","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T11:36:22Z","timestamp":1614684982000},"page":"833","source":"Crossref","is-referenced-by-count":376,"title":["Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia"],"prefix":"10.1001","volume":"325","author":[{"given":"Patrick A.","family":"Brown","sequence":"first","affiliation":[{"name":"Departments of Oncology and Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Xu","sequence":"additional","affiliation":[{"name":"Children's Oncology Group, Monrovia, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi","family":"Devidas","sequence":"additional","affiliation":[{"name":"Department of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"Hogan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Stony Brook Children\u2019s, Stony Brook, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Borowitz","sequence":"additional","affiliation":[{"name":"Departments of Pathology and Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Raetz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, NYU Langone Health, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Zugmaier","sequence":"additional","affiliation":[{"name":"Amgen Research (Munich), GmbH, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Sharon","sequence":"additional","affiliation":[{"name":"Division of Cancer Treatment and Diagnosis, National Cancer Institute, Cancer Therapy Evaluation Program, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie B.","family":"Bernhardt","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie A.","family":"Terezakis","sequence":"additional","affiliation":[{"name":"University of Minnesota, Department of Radiation Oncology, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia","family":"Gore","sequence":"additional","affiliation":[{"name":"University of Colorado School of Medicine and Center for Cancer and Blood Disorders, Children\u2019s Hospital Colorado, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Whitlock","sequence":"additional","affiliation":[{"name":"Hospital for Sick Children and University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Pulsipher","sequence":"additional","affiliation":[{"name":"Transplantation and Cellular Therapy, Children's Hospital Los Angeles Cancer and Blood Diseases Institute, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Hunger","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and the Center for Childhood Cancer Research, Children's Hospital of Philadelphia and The Perelman School of Medicine at The University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mignon L.","family":"Loh","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Benioff Children\u2019s Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"joi210007r1","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1038\/leu.2008.251","article-title":"Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children\u2019s Oncology Group study.","volume":"22","author":"Nguyen","year":"2008","journal-title":"Leukemia"},{"issue":"2","key":"joi210007r2","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/bjh.15919","article-title":"Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children\u2019s Oncology Group.","volume":"186","author":"Horton","year":"2019","journal-title":"Br J Haematol"},{"issue":"7","key":"joi210007r3","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1002\/pbc.25454","article-title":"Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): phase II results from Children\u2019s Oncology Group (COG) study ADVL04P2.","volume":"62","author":"Raetz","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"9757","key":"joi210007r4","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1016\/S0140-6736(10)62002-8","article-title":"Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.","volume":"376","author":"Parker","year":"2010","journal-title":"Lancet"},{"issue":"14","key":"joi210007r5","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.2009.25.1983","article-title":"Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90.","volume":"28","author":"Tallen","year":"2010","journal-title":"J Clin Oncol"},{"issue":"14","key":"joi210007r6","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1182\/blood-2012-02-265884","article-title":"How I treat relapsed childhood acute lymphoblastic leukemia.","volume":"120","author":"Locatelli","year":"2012","journal-title":"Blood"},{"issue":"4","key":"joi210007r7","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26909","article-title":"Treatment-related mortality in relapsed childhood acute lymphoblastic leukemia.","volume":"65","author":"Oskarsson","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"22","key":"joi210007r8","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1182\/blood-2014-12-615757","article-title":"IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients.","volume":"125","author":"Pulsipher","year":"2015","journal-title":"Blood"},{"issue":"21","key":"joi210007r9","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1182\/bloodadvances.2019000449","article-title":"More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling.","volume":"3","author":"Bader","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"joi210007r10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3324\/haematol.2019.237230","article-title":"Outcomes after late bone marrow and very early central nervous system relapse of childhood B-Acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433.","volume":"106","author":"Lew","year":"2021","journal-title":"Haematologica"},{"issue":"36","key":"joi210007r11","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1200\/JCO.19.01694","article-title":"Improving stratification for children with late bone marrow B-cell acute lymphoblastic leukemia relapses with refined response classification and integration of genetics.","volume":"37","author":"Eckert","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"joi210007r12","doi-asserted-by":"publisher","first-page":"e204","DOI":"10.1016\/S2352-3026(19)30003-1","article-title":"Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial.","volume":"6","author":"Parker","year":"2019","journal-title":"Lancet Haematol"},{"issue":"9","key":"joi210007r13","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia.","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"36","key":"joi210007r14","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase i\/phase ii study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia.","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"J Clin Oncol"},{"issue":"14","key":"joi210007r15","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"issue":"12","key":"joi210007r16","doi-asserted-by":"publisher","first-page":"5477","DOI":"10.1182\/blood-2008-01-132837","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children\u2019s Oncology Group study.","volume":"111","author":"Borowitz","year":"2008","journal-title":"Blood"},{"issue":"1","key":"joi210007r17","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/cyto.b.21482","article-title":"A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia\/lymphoma post anti-CD19 therapy.","volume":"94","author":"Cherian","year":"2018","journal-title":"Cytometry B Clin Cytom"},{"issue":"28","key":"joi210007r18","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1200\/JCO.20.00256","article-title":"Children\u2019s Oncology Group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia.","volume":"38","author":"Dunsmore","year":"2020","journal-title":"J Clin Oncol"},{"issue":"20","key":"joi210007r19","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1200\/JCO.2015.62.4544","article-title":"Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk b-acute lymphoblastic leukemia: a report from Children\u2019s Oncology Group study AALL0232.","volume":"34","author":"Larsen","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"joi210007r20","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2307\/2336502","article-title":"Discrete sequential boundaries for clinical trials.","volume":"70","author":"Lan","year":"1983","journal-title":"Biometrika."},{"issue":"3","key":"joi210007r21","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2307\/2530245","article-title":"A multiple testing procedure for clinical trials.","volume":"35","author":"O\u2019Brien","year":"1979","journal-title":"Biometrics"},{"issue":"4","key":"joi210007r22","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S0197-2456(02)00218-0","article-title":"A comment on futility monitoring.","volume":"23","author":"Freidlin","year":"2002","journal-title":"Control Clin Trials"},{"issue":"3","key":"joi210007r24","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals.","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"issue":"8","key":"joi210007r25","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia.","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"joi210007r26","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia.","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"joi210007r23","doi-asserted-by":"crossref","DOI":"10.1002\/9781118032985","volume-title":"The Statistical Analysis of Failure Time Data","author":"Kalbfleisch","year":"2002"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2776879\/jama_brown_2021_oi_210007_1614619907.67498.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T04:34:16Z","timestamp":1697949256000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2776879"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2021,3,2]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,3,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2021.0669","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.739661899.793585876","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.739661899.793584165","asserted-by":"object"}]},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3,2]]}}}